Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.

Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB; A5264/AMC-067 REACT-KS Team.

Clin Infect Dis. 2018 Jul 2;67(2):251-260. doi: 10.1093/cid/ciy044.

2.

A biobank to support HIV malignancy research for sub-Saharan Africa.

Schneider JW, Sanderson M, Geiger D, Nokta M, Silver S.

S Afr Med J. 2016 Aug 2;106(9):867-9. doi: 10.7196/SAMJ.2016.v106i9.10891.

3.

Improving acquired immunodeficiency syndrome related cancer outcomes through international collaboration.

Nokta M.

Chin J Integr Med. 2011 May;17(5):326-8. doi: 10.1007/s11655-011-0612-7. Epub 2011 May 25. No abstract available.

PMID:
21611893
4.

In vitro cell-mediated immune responses of human immunodeficiency virus-infected and -uninfected individuals to whole cytomegalovirus antigens and their subunits.

Weinberg A, Spritzler J, Nokta M, Schrier R, Landay A, Brown D, Pollard R; ACTG CMV Task Force.

Clin Vaccine Immunol. 2008 Sep;15(9):1398-409. doi: 10.1128/CVI.00479-07. Epub 2008 Jun 25.

5.

Oral manifestations associated with HIV infection.

Nokta M.

Curr HIV/AIDS Rep. 2008 Feb;5(1):5-12. Review.

PMID:
18417029
6.

The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.

Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ; ACTG 379 Study Team.

HIV Clin Trials. 2005 May-Jun;6(3):136-46.

PMID:
16192248
7.

Cell cycle kinetic dysregulation in HIV-infected normal lymphocytes.

Asmuth DM, Wang N, Lu Y, Li XD, Reece L, Terry NH, Pollard RB, Nokta M, Leary JF, White RA.

Cytometry A. 2005 Jul;66(1):41-51.

8.

Estimating cell death in G(2)M using bivariate BrdUrd/DNA flow cytometry.

White RA, Asmuth DM, Lu Y, Wang N, Li XD, Reece L, Pollard RB, Nokta M, Leary JF, Terry NH.

Cytometry A. 2005 Jul;66(1):32-40.

9.

A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis.

Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, Aweeka F, Nadler PI, Sattler F, Alston B, Nevin TT, Owens S, Waterman K, Hubbard L, Caliendo A, Pollard RB; AACTG 266 Team.

Antiviral Res. 2004 Nov;64(2):103-11.

PMID:
15498605
10.

Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12.

Sha BE, Onorato M, Bartlett JA, Bosch RJ, Aga E, Nokta M, Adams EM, Li XD, Eldridge J, Pollard RB.

AIDS. 2004 May 21;18(8):1203-6.

PMID:
15166537
11.

Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response.

Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A.

J Infect Dis. 2004 May 15;189(10):1811-20. Epub 2004 Apr 29.

PMID:
15122517
12.

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2304-15.

13.

Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients: association with HIV cellular viral load.

Nokta MA, Li XD, Al-Harthi L, Nichols J, Pou A, Asmuth D, Landay A, Pollard RB.

AIDS. 2002 Nov 8;16(16):2119-27.

14.

Cytomegalovirus (CMV) polymerase chain reaction profiles in individuals with advanced human immunodeficiency virus infection: relationship to CMV disease.

Nokta MA, Holland F, De Gruttola V, Emery VC, Jacobson MA, Griffiths P, Pollard RB, Feinberg JE; AIDS Clinical Trials Group, Protocol 204/GlaxoWellcome 123-014, International CMV Prophylaxis Study Group.

J Infect Dis. 2002 Jun 15;185(12):1717-22. Epub 2002 May 31.

PMID:
12085316
15.
16.

Homeostasis of naive and memory T cell subpopulations in peripheral blood and lymphoid tissues in the context of human immunodeficiency virus infection.

Nokta MA, Li XD, Nichols J, Pou A, Asmuth D, Pollard RB.

J Infect Dis. 2001 May 1;183(9):1336-42. Epub 2001 Mar 27.

PMID:
11294664
17.

Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals.

Nokta MA, Li XD, Nichols J, Mallen M, Pou A, Asmuth D, Pollard RB.

AIDS. 2001 Jan 26;15(2):161-9.

PMID:
11216923
18.

Co-receptor usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: is NSI/SI phenotyping sufficient?

Lathey JL, Brambilla D, Goodenow MM, Nokta M, Rasheed S, Siwak EB, Bremer JW, Huang DD, Yi Y, Reichelderfer PS, Collman RG.

J Leukoc Biol. 2000 Sep;68(3):324-30.

PMID:
10985247
19.

Shipment impairs lymphocyte proliferative responses to microbial antigens.

Betensky RA, Connick E, Devers J, Landay AL, Nokta M, Plaeger S, Rosenblatt H, Schmitz JL, Valentine F, Wara D, Weinberg A, Lederman HM.

Clin Diagn Lab Immunol. 2000 Sep;7(5):759-63.

20.

Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation.

Fahey JL, Aziz N, Spritzler J, Plaeger S, Nishanian P, Lathey JL, Seigel J, Landay AL, Kilarui R, Schmitz JL, White C, Wara DW, Akridge R, Cutili J, Douglas SD, Reuben J, Shearer WT, Nokta M, Polland R, Schooley R, Asthana D, Mizrachi Y, Waxdal M.

Clin Diagn Lab Immunol. 2000 Jul;7(4):540-8.

21.

Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels.

Sha BE, Johnson VA, Kendall MA, Haubrich R, Nokta M, Lamb K, Zackin RA, Nail CD, Currier JS.

AIDS. 2000 Apr 14;14(6):746-8. No abstract available.

PMID:
10807200
22.
23.

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, Chou S, Drew WL, Erice A, Gilliam B, Lurain N, Manischewitz J, Miner R, Nokta M, Reichelderfer P, Spector S, Weinberg A, Yen-Lieberman B, Crumpacker C.

Antimicrob Agents Chemother. 2000 Mar;44(3):688-92.

24.

Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations.

Nokta M, Rossero R, Nichols J, Rosenbaum M, Pollard RB.

AIDS Res Hum Retroviruses. 1999 Feb 10;15(3):255-64.

PMID:
10052756
25.

Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.

McSharry JM, Lurain NS, Drusano GL, Landay A, Manischewitz J, Nokta M, O'Gorman M, Shapiro HM, Weinberg A, Reichelderfer P, Crumpacker C.

J Clin Microbiol. 1998 Apr;36(4):958-64.

26.

HIV decreases glutamate transport in SK-N-MC neuroblastoma cells.

Pappas TC, Alagarsamy S, Pollard RB, Nokta M.

J Neurovirol. 1998 Feb;4(1):69-79.

PMID:
9531013
27.
28.

Emerging treatments for viral retinitis.

Nokta MA, Hausrath SG, Pollard RB.

BioDrugs. 1997 Jun;7(6):423-32.

PMID:
18020490
30.

HIV-induced TNF-alpha regulates arachidonic acid and PGE2 release from HIV-infected mononuclear phagocytes.

Nokta MA, Hassan MI, Loesch KA, Pollard RB.

Virology. 1995 Apr 20;208(2):590-600.

31.

Protein kinase C and intracellular free Ca++: relationship to human immunodeficiency virus (HIV)-induced cellular hyporesponsiveness.

Nokta MA, Hassan MI, Morgan JA, Loesch KA, Pollard RB.

Proc Soc Exp Biol Med. 1994 Dec;207(3):284-91.

PMID:
7800684
32.
33.
34.

Involvement of cAMP and protein kinase C in cytomegalovirus enhancement of human immunodeficiency virus replication.

Hassan MI, Nokta MA, Pollard RB.

Proc Soc Exp Biol Med. 1993 Nov;204(2):216-23.

PMID:
8415779
35.

Papaverine hydrochloride: effects on HIV replication and T-lymphocyte cell function.

Nokta M, Albrecht T, Pollard R.

Immunopharmacology. 1993 Sep-Oct;26(2):181-5.

PMID:
7506701
36.

Human immunodeficiency virus replication: modulation by cellular levels of cAMP.

Nokta MA, Pollard RB.

AIDS Res Hum Retroviruses. 1992 Jul;8(7):1255-61.

PMID:
1381600
37.

X-irradiation enhances in vitro human immunodeficiency virus replication correlation with cellular levels of cAMP.

Nokta M, Belli J, Pollard R.

Proc Soc Exp Biol Med. 1992 Jul;200(3):402-8.

PMID:
1352047
38.

Recombinant human interferon beta ser protects against zidovudine-induced genetic damage in AIDS patients.

Shafik HM, Nokta MA, Pollard RB.

Antiviral Res. 1991 Sep;16(2):205-12.

PMID:
1799278
39.

Metabolic interaction of recombinant interferon-beta and zidovudine in AIDS patients.

Nokta M, Loh JP, Douidar SM, Ahmed AE, Pollard RB.

J Interferon Res. 1991 Jun;11(3):159-64.

PMID:
1919075
40.

In vivo administration of tumor necrosis factor-alpha is associated with antiviral activity in human peripheral mononuclear cells.

Nokta M, Matzke D, Jennings M, Schlick E, Nadler PI, Pollard R.

Proc Soc Exp Biol Med. 1991 Jun;197(2):144-9.

PMID:
1709503
41.

Comparative disposition and whole-body autoradiographic distribution of [2-14C]azidothymidine and [2-14C]thymidine in mice.

Ahmed AE, Jacob S, Loh JP, Samra SK, Nokta M, Pollard RB.

J Pharmacol Exp Ther. 1991 Apr;257(1):479-86.

PMID:
2020004
43.

Amiloride inhibition of human cytomegalovirus replication.

Fons M, Nokta M, Cerruti-Sola S, Albrecht T.

Proc Soc Exp Biol Med. 1991 Jan;196(1):89-96.

PMID:
1845780
46.

Cytomegalovirus: sodium entry and development of cytomegaly in human fibroblasts.

Nokta M, Fons MP, Eaton DC, Albrecht T.

Virology. 1988 Jun;164(2):411-9.

PMID:
2835859
47.

Ca2+ responses in cytomegalovirus-infected fibroblasts of human origin.

Nokta M, Eaton D, Steinsland OS, Albrecht T.

Virology. 1987 Apr;157(2):259-67.

PMID:
3029971
48.

Cellular responses to human cytomegalovirus infection.

Albrecht T, Li JL, Speelman D, Ball R, Nokta M, Fons M, Lee CH, Steinsland O, Thompson WC, Carney DH.

Birth Defects Orig Artic Ser. 1984;20(1):21-34. No abstract available.

PMID:
6329362

Supplemental Content

Support Center